Paraoxonase (PON1) and the risk for coronary heart disease and myocardial infarction in a general population of Dutch women

Atherosclerosis

Volumn 199, Issue 2, 2008, Pages 408-414

  van Himbergen, Thomas M ^a,b   van der Schouw, Yvonne T ^a   Voorbij, Hieronymus A M ^a   van Tits, Lambertus J H ^b   Stalenhoef, Anton F H ^b   Peeters, Petra H M ^a   Roest, Mark ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Epidemiology; Myocardial infarction; Paraoxonase; Smoking; Women

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLESTERASE;

ACUTE HEART INFARCTION; ADULT; AGE DETERMINATION; AGED; ARTICLE; CARDIOVASCULAR RISK; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; ENZYME ACTIVITY; FEMALE; GENE ACTIVITY; GENETIC VARIABILITY; GENOTYPE; HAZARD RATIO; HEART INFARCTION; HUMAN; INCIDENCE; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; METHODOLOGY; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; RANDOM SAMPLE; SMOKING; STATISTICAL MODEL;

AGED; ARYLDIALKYLPHOSPHATASE; COHORT STUDIES; CORONARY DISEASE; FEMALE; GENOTYPE; HUMANS; MIDDLE AGED; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; NETHERLANDS; PROPORTIONAL HAZARDS MODELS; PROSPECTIVE STUDIES; RISK; SMOKING;

EID: 47649105203     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2007.11.018     Document Type: Article

References (44)

1. Draganov D.I., Teiber J.F., Speelman A., Osawa Y., Sunahara R., and La Du B.N. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. J Lipid Res 46 (2005) 1239-1247
2. Humbert R., Adler D.A., Disteche C.M., Hassett C., Omiecinski C.J., and Furlong C.E. The molecular basis of the human serum paraoxonase activity polymorphism. Nat Genet 3 (1993) 73-76
3. Davies H.G., Richter R.J., Keifer M., Broomfield C.A., Sowalla J., and Furlong C.E. The effect of the human serum paraoxonase polymorphism is reversed with diazoxon, soman and sarin. Nat Genet 14 (1996) 334-336
4. Shih D.M., Gu L., Xia Y.R., et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature 394 (1998) 284-287
5. Ng C.J., Shih D.M., Hama S.Y., Villa N., Navab M., and Reddy S.T. The paraoxonase gene family and atherosclerosis. Free Radic Biol Med 38 (2005) 153-163
6. Adkins S., Gan K.N., Mody M., and La Du B.N. Molecular basis for the polymorphic forms of human serum paraoxonase/arylesterase: glutamine or arginine at position 191, for the respective A or B allozymes. Am J Hum Genet 52 (1993) 598-608
7. Brophy V.H., Jampsa R.L., Clendenning J.B., McKinstry L.A., Jarvik G.P., and Furlong C.E. Effects of 5′ regulatory-region polymorphisms on paraoxonase-gene (PON1) expression. Am J Hum Genet 68 (2001) 1428-1436
8. Kujiraoka T., Oka T., Ishihara M., et al. A sandwich enzyme-linked immunosorbent assay for human serum paraoxonase concentration. J Lipid Res 41 (2000) 1358-1363
9. Eckerson H.W., Wyte C.M., and La Du B.N. The human serum paraoxonase/arylesterase polymorphism. Am J Hum Genet 35 (1983) 1126-1138
10. Richter R.J., and Furlong C.E. Determination of paraoxonase (PON1) status requires more than genotyping. Pharmacogenetics 9 (1999) 745-753
11. Costa L.G., Cole T.B., Jarvik G.P., and Furlong C.E. Functional genomic of the paraoxonase (PON1) polymorphisms: effects on pesticide sensitivity, cardiovascular disease, and drug metabolism. Annu Rev Med 54 (2003) 371-392
12. Wheeler J.G., Keavney B.D., Watkins H., Collins R., and Danesh J. Four paraoxonase gene polymorphisms in 11212 cases of coronary heart disease and 12786 controls: meta-analysis of 43 studies. Lancet 363 (2004) 689-695
13. Nishio E., and Watanabe Y. Cigarette smoke extract inhibits plasma paraoxonase activity by modification of the enzyme's free thiols. Biochem Biophys Res Commun 236 (1997) 289-293
14. James R.W., Leviev I., and Righetti A. Smoking is associated with reduced serum paraoxonase activity and concentration in patients with coronary artery disease. Circulation 101 (2000) 2252-2257
15. van der Gaag M.S., van Tol A., Scheek L.M., et al. Daily moderate alcohol consumption increases serum paraoxonase activity; a diet-controlled, randomised intervention study in middle-aged men. Atherosclerosis 147 (1999) 405-410
16. Mackness B., Davies G.K., Turkie W., et al. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype?. Arterioscler Thromb Vasc Biol 21 (2001) 1451-1457
17. Mackness M., and Mackness B. Paraoxonase 1 and atherosclerosis: is the gene or the protein more important?. Free Radic Biol Med 37 (2004) 1317-1323
18. Jarvik G.P., Rozek L.S., Brophy V.H., et al. Paraoxonase (PON1) phenotype is a better predictor of vascular disease than is PON1(192) or PON1(55) genotype. Arterioscler Thromb Vasc Biol 20 (2000) 2441-2447
19. Mackness B., Durrington P., McElduff P., et al. Low paraoxonase activity predicts coronary events in the Caerphilly prospective study. Circulation 107 (2003) 2775-2779
20. Troughton JA, Woodside JV, Yarnell JW, et al. Paraoxonase activity and coronary heart disease risk in healthy middle-aged males: the PRIME study. Atherosclerosis 2007
21. Boker L.K., van Noord P.A., van der Schouw Y.T., et al. Prospect-EPIC Utrecht: study design and characteristics of the cohort population. European prospective investigation into cancer and nutrition. Eur J Epidemiol 17 (2001) 1047-1053
22. van der A.D., Marx J.J., Grobbee D.E., et al. Non-transferrin-bound iron and risk of coronary heart disease in postmenopausal women. Circulation 113 (2006) 1942-1949
23. Herings R.M., Bakker A., Stricker B.H., and Nap G. Pharmaco-morbidity linkage: a feasibility study comparing morbidity in two pharmacy based exposure cohorts. J Epidemiol Community Health 46 (1992) 136-140
24. Roest M., van Himbergen T.M., Barendrecht A.B., Peeters P.H., van der Schouw Y.T., and Voorbij H.A. Genetic and environmental determinants of the PON-1 phenotype. Eur J Clin Invest 37 (2007) 187-196
25. Prentice R.L. A case-cohort design for epidemiologic cohort studies and disease prevention trials. Biometrika 73 (1986) 1-11
26. Barlow W.E., Ichikawa L., Rosner D., and Izumi S. Analysis of case-cohort designs. J Clin Epidemiol 52 (1999) 1165-1172
27. Aviram M., Billecke S., Sorenson R., et al. Paraoxonase active site required for protection against LDL oxidation involves its free sulfhydryl group and is different from that required for its arylesterase/paraoxonase activities: selective action of human paraoxonase allozymes Q and R. Arterioscler Thromb Vasc Biol 18 (1998) 1617-1624
28. Mackness B., Mackness M.I., Arrol S., Turkie W., and Durrington P.N. Effect of the human serum paraoxonase 55 and 192 genetic polymorphisms on the protection by high density lipoprotein against low density lipoprotein oxidative modification. FEBS Lett 423 (1998) 57-60
29. Aviram M., Hardak E., Vaya J., et al. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Circulation 101 (2000) 2510-2517
30. Khersonsky O., and Tawfik D.S. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Biochemistry 44 (2005) 6371-6382
31. Harel M., Aharoni A., Gaidukov L., et al. Structure and evolution of the serum paraoxonase family of detoxifying and anti-atherosclerotic enzymes. Nat Struct Mol Biol 11 (2004) 412-419
32. Khersonsky O., and Tawfik D.S. The histidine 115-histidine 134 dyad mediates the lactonase activity of mammalian serum paraoxonases. J Biol Chem 281 (2006) 7649-7656
33. Ferre N., Camps J., Fernandez-Ballart J., et al. Regulation of serum paraoxonase activity by genetic, nutritional, and lifestyle factors in the general population. Clin Chem 49 (2003) 1491-1497
34. Rios D.L., D'Onofrio L.O., Cerqueira C.C., et al. Paraoxonase 1 gene polymorphisms in angiographically assessed coronary artery disease: evidence for gender interaction among Brazilians. Clin Chem Lab Med 45 (2007) 874-878
35. Beer S., Moren X., Ruiz J., and James R.W. Postprandial modulation of serum paraoxonase activity and concentration in diabetic and non-diabetic subjects. Nutr Metab Cardiovasc Dis 16 (2006) 457-465
36. Cabana V.G., Reardon C.A., Feng N., Neath S., Lukens J., and Getz G.S. Serum paraoxonase: effect of the apolipoprotein composition of HDL and the acute phase response. J Lipid Res 44 (2003) 780-792
37. Feingold K.R., Memon R.A., Moser A.H., and Grunfeld C. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Atherosclerosis 139 (1998) 307-315
38. Van Lenten B.J., Wagner A.C., Nayak D.P., Hama S., Navab M., and Fogelman A.M. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Circulation 103 (2001) 2283-2288
39. Van Lenten B.J., Hama S.Y., de Beer F.C., et al. Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures. J Clin Invest 96 (1995) 2758-2767
40. Steinberg D. Atherogenesis in perspective: hypercholesterolemia and inflammation as partners in crime. Nat Med 8 (2002) 1211-1217
41. Shah P.K. Mechanisms of plaque vulnerability and rupture. J Am Coll Cardiol 41 (2003) 15S-22S
42. van Himbergen T.M., Roest M., de Graaf J., et al. Indications that paraoxonase-1 contributes to plasma high density lipoprotein levels in familial hypercholesterolemia. J Lipid Res 46 (2005) 445-451
43. van Himbergen T.M., van Tits L.J., Hectors M.P., de Graaf J., Roest M., and Stalenhoef A.F. Paraoxonase-1 and linoleic acid oxidation in familial hypercholesterolemia. Biochem Biophys Res Commun 333 (2005) 787-793
44. Mertens A., and Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. Faseb J 15 (2001) 2073-2084